Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
DNTH-103 by Dianthus Therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval
DNTH-103 is under clinical development by Dianthus Therapeutics and currently in Phase I for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According...
Data Insights
DNTH-103 by Dianthus Therapeutics for Multifocal Motor Neuropathy: Likelihood of Approval
DNTH-103 is under clinical development by Dianthus Therapeutics and currently in Phase II for Multifocal Motor Neuropathy. According to GlobalData,...